UBS Group Begins Coverage on Bruker (NASDAQ:BRKR)

Equities research analysts at UBS Group assumed coverage on shares of Bruker (NASDAQ:BRKR) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The brokerage set a “neutral” rating and a $65.00 price target on the medical research company’s stock. UBS Group’s price target would suggest a potential upside of 11.36% from the company’s current price.

BRKR has been the topic of a number of other research reports. Citigroup decreased their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. TD Cowen reiterated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Wolfe Research initiated coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. Zacks Research lowered shares of Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. raised their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $57.00.

Bruker Stock Performance

Shares of BRKR stock opened at $58.37 on Wednesday. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. Bruker has a 12 month low of $30.09 and a 12 month high of $65.30. The company has a market cap of $8.89 billion, a P/E ratio of -83.39, a PEG ratio of 1.79 and a beta of 1.26. The firm has a fifty day moving average price of $58.70 and a 200 day moving average price of $49.00.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. During the same quarter last year, the company posted $0.32 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts predict that Bruker will post 2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bruker

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Los Angeles Capital Management LLC bought a new position in shares of Bruker in the fourth quarter valued at approximately $26,000. Global Retirement Partners LLC purchased a new position in shares of Bruker in the second quarter worth approximately $38,000. Parallel Advisors LLC lifted its holdings in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. Allworth Financial LP grew its stake in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Finally, Essential Partners LLC purchased a new stake in Bruker in the 1st quarter worth approximately $36,000. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.